The current state of the problem of inflammatory diseases of the uterine appendages: diagnosis and treatment

Objective. To evaluate the current view on the problem of diagnosis and treatment of chronic inflammatory diseases of uterine adnexa (CIDUA).

Materials and methods. A search was performed in PubMed electronic databases, eLIBRARY.RU, «CyberLeninka» using the terms «chronic inflammatory diseases of the uterine adnexa», «chronic salpingoophoritis», «pelvic inflammatory diseases», «diagnosis», «treatment» in various combinations. 130 references were received, 50 articles in English, French and Russian were selected.

Results. Additional diagnostic methods include the assessment of immunological biomarkers of inflammation (interleukins 1ß, 4, 6; tumor necrosis factor α) in the blood. An increased expression of the B-cell activation factor was found in whole tissue samples of patients with CIDUA. The average platelet volume is significantly reduced in patients with CIDUA, so this indicator can serve as a more valuable marker than the number of white blood cells. In patients with CIDUA, there is a significant increase in the level of lipid peroxidation products. The inclusion of the immunomodulator aminodihydrophthalazinedione sodium in the treatment of CIDUA allows you to restore the disturbed immunological balance. Therapy with the inclusion of bov azoximer hyaluronidase leads to an improvement in the rheological properties of blood. 1 month after treatment with antioxidants, normal indicators of lipid peroxidation are noted. The effectiveness of the use of plasmapheresis, ultraviolet illumination of blood, laser therapy and ozone is shown. Hyperbaric oxygen has a bactericidal effect.

Conclusions. The problem of CIDUA remains one of the most urgent at the present time. Therefore, modern aspects of diagnosis (determination of immunological biomarkers of inflammation, expression of B-cell activation factor, average platelet volume, the level of intermediate products of lipid peroxidation) and treatment (use of immunomodulators, antioxidants, plasmapheresis, ultraviolet illumination of blood, ozone therapy, laser therapy and hyperbaric oxygen therapy) are quite relevant.

1. Abramova S. V., Korobkov D. M. Survey look at the problem of subsidiary reproductive technologies. Bulletin of Science and Practice. 2017;8(21):120–127. doi: 10.5281/zenodo.842907 (in Russ.).

2. Savelyeva G. M., Sukhoi G. T., Serov V. N. et al. Gynecology: national guide. M.: GEOTAR-Media. 2020. 1056 p. (in Russ.).

3. Shlyapnikov M. E., Belokonev V. I., Prokhorova L. V. et al. Clinical and microbiological characteristics of patients with inflammatory destructive tumors of the uterine appendages. Topical issues of diagnosis, treatment and rehabilitation of patients: Materials of the XVIII Interregional Scientific and Practical Conference of the Penza Institute of Advanced Training of Doctors of the Ministry of Health of the Russian Federation [Electronic resource], Penza, October 27, 2016. – Penza: Penza State University. 2016;288–291 (in Russ.).

4. Canadian Guidelines on Sexually Transmitted Infections – Management and treatment of specific syndromes – Pelvic Inflammatory Disease (PID). 2016.

5. Gasparyan A. C., Kaprinin V. M., Sidorchuk A. V. Modern methods of diagnosis and treatment of urogenital chlamydia. Obstetrics and gynecology. 2017;1:159–160 (in Russ.).

6. Schalkwyk J., Yudin M. H. Infectious disease committee. Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis and bacterial vaginosis. J. Obstet. Gynaecol. Can. 2015;37(3):266–274. doi: 10.1016/S1701–2163(15)30316-9

7. Akker L. V. Diagnosis of gynecological pathology accompanied by chronic pelvic pain. 18 All-Russian Scientific Forum with international participation «Mother and healthy child»: materials. Moskow. 2016;317–318 (in Russ.).

8. Aksenenko V. A., Zhikhareva I. V., Lavrinenko E. B. Features of laparoscopic treatment of inflammatory diseases of the uterine appendages of chlamydial etiology. Endoscopy in gynecology / edited by L. V. Adamyan. M., 2015;448–449 (in Russ.).

9. Sivakova S. D. The possibilities of the ultrasound method of investigation in the diagnosis of chronic endometritis. Science Time. 2021;9(93):35–39. (in Russ.).

10. Yudina E. A., Konoplya A. A., Lazarev A. I. et al. The use of longidase in the treatment of exacerbations of chronic salpingoophoritis. Kursk scientific and practical bulletin Man and his health. 2008;3:104–110 (in Russ.).

11. Dobrokhotova Yu.E., Saprykina L. V., Saprykina O. A. HPV-associated lesions of the skin and mucous membranes of the female genital organs. Possibilities of local therapy. Breast cancer. Mother and child. 2018;1(1):57–61 (in Russ.).

12. Yurasov I. V. Modern aspects of tactics in inflammatory diseases of the pelvic organs in women. abstract of the dissertation. … Doctors of Medical Sciences. Volgograd State Medical University. Volgograd. 2015;45 (in Russ.).

13. Taylor-Robinson D., Jensen J. S., Svenstrup H. et al. Difficulties experienced in defining the microbial cause of pelvic inflammatory disease. Int J. STD AIDS. 2012;23(1):18–24. doi: 10.1258/ijsa.2011.011066

14. Zhao W., Hao M. Pelvic inflammatory disease: a retrospective clinical analysis of 1,922 cases in North China. Gynecol. Obstet. Invest. 2014;77(3):169–75. doi: 10.1159/000358393

15. Ross J., Guaschino S., Cusini M. et al. 2017. European guideline for the management of pelvic inflammatory disease. Int J. STD AIDS. 2018;29(2):108–114. doi: 10.1177/0956462417744099

16. Derniaux E., Lucereau-Barbier M., Graesslin O. Follow-up and counselling after pelvic inflammatory disease. J. Gynecol. Obstet. Biol. Reprod. 2012;41(8):922–9. doi: 10.1016/j.jgyn.2012.09.023

17. Gremeau A. S., Girard A., Lambert C. et al. Benefits of second-look laparoscopy in the management of pelvic inflammatory disease. J. Gynecol. Obstet. Hum. Reprod. 2019;48(6):413–417. doi: 10.1016/j.jogoh.2019.03.020

18. Li W., Zhang Y., Cui Y. et al. Pelvic inflammatory disease: evaluation of diagnostic accuracy with conventional MR with added diffusion-weighted imaging. Abdom. Imaging. 2013;38(1):193–200. doi: 10.1007/s00261-012-9896-0

19. Romosan G., Valentin L. The sensitivity and specificity of transvaginal ultrasound with regard to acute pelvic inflammatory disease: a review of the literature. Archives of Gynecology and Obstetrics. 2014;289:705–714. doi: 10.1007/s00404-013-3091-6

20. Romosan G., Bjartling C., Skoog L. et al. Ultrasound for diagnosing acute salpingitis: a prospective observational diagnostic study. Human. Reproduction. 2013;28 (6):1569–1579. https://doi.org/10.1093/humrep/det065

21. Stepanova Yu.V., Shatunova E. P. Clinical and immunological characteristics of inflammatory diseases of uterine appendages I. Practical medicine. 2012;9(65):65–68 (in Russ.).

22. Chebotarev V. V., Pavlov R. V., Aksenenko V. A. Features of microflora and production of individual cytokines in fallopian tube tissue in chronic inflammation. Medical Bulletin of the North Caucasus. 2013;8(2):72–74 (in Russ.).

23. Xu J., Luo X., Qu S. et al. B cell activation factor (BAFF) induces inflammation in the human fallopian tube leading to tubal pregnancy. BMC Pregnancy Childbirth. 2019;19(1):169. doi: 10.1186/s12884-019-2324-5

24. Incebiyik A., Seker A., Vural M. et al. May mean platelet volume levels be a predictor in the diagnosis of pelvic inflammatory disease? Wien KlinWochenschr. 2014;126(13–14):422–6. doi: 10.1007/s00508-014-0560-2

25. Marzieva T. A., Rogozhina I. E., Glukhova T. N. On the expediency of using antioxidants in the complex therapy of acute salpingooophoritis. The Attending Physician. 2021;3(24):26–28. doi: 10.51793/OS.2021.24.3.005 (in Russ.).

26. Brunham R. C., Gottlieb S. L., Paavonen J. Pelvic Inflammatory Disease. N. Engl. J. Med. 2015;372:2039–48. doi: 10.1056/NEJMra1411426

27. Ross J., Roads P. M., Ross J. Can ceftriaxone be omitted in the treatment of nongonococcal pelvic inflammatory disease? Int J. STD AIDS. 2021;32(10):981–982. doi: 10.1177/09564624211004415

28. Jensen J., Salado-Rasmussen K. Sexually transmitted Mycoplasma genitalium infection is difficult to treat. UgeskrLaeger. 2018;180(20): V01180038.

29. Kirkcaldy R. D., Bolan G. A., Wasserheit J. N. Cephalosporin-resistant gonorrhea in North America. JAMA. 2013;309:185–7. doi: 10.1001/jama.2012.205107

30. Haggerty C., Totten P., Tang G. et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. SexTransmInfect. 2016;92(6):441–6. doi: 10.1136/sextrans-2015–052285

31. Dhasmana D., Hathorn E., McGrath R. et al. The effectiveness of nonsteroidal anti-inflammatory agents in the treatment of pelvic inflammatory disease: a systematic review. SystRev. 2014;3:79. doi: 10.1186/2046-4053-3-79

32. Savaris R., Fuhrich D., Maissiat J. et al. Antibiotic therapy for pelvic inflammatory disease. Cochrane Database Syst Rev. 2020;8(8): CD 010285. doi: 10.1002/14651858.CD010285.pub3

33. Ziganshin A. M., Mudrov V. A. Optimization of complex therapy of inflammatory diseases of the pelvic organs in women. Gynecology. 2019;21(3):30–34. doi: 10.26442/20795696.2019.3.190465 (in Russ.).

34. Asrankulova D. B., Akhmedova N. M., Kamildzhanova G. I. Features of vascular-platelet and coagulation hemostasis in women with inflammatory diseases of the uterine appendages. Re-health Journal. 2020;1(5):4–7. doi:10.24411/2181–0443/2020–10002 (in Russ.).

35. Khasanova V. V., Kukarskaya I. I., Shevlyukova T. P. et al. A modern approach to the combination therapy of patients with inflammatory diseases of the pelvic organs. Perm. Medical Journal. 2021;38(2):45–55. doi:10.17816/pmj38245–55 (in Russ.).

36. Fedorova T. A., Strelnikova E. V. Combined use of plasmapheresis and ultraviolet blood screening in the treatment of patients with chronic recurrent salpingoophoritis. Bulletin of New Medical Technologies. 2018;25(1):29–43. doi:10.24411/1609-2163-2018-15961 (in Russ.).

37. Moskvin S. V. Fundamentals of laser therapy. Series «Effective laser therapy». Moscow, Tver: LLC «Publishing House «Triada». 2016. 896 p. (in Russ.).

38. Barone A., Otero-Losada M., Grangeat A. M. et al. Ozonetherapy protects from in-stent coronary neointimal proliferation. Role of redoxins. International Journal of Cardiology. 2016;223:258–61. doi: 10.1016/j.ijcard.2016.07.177

39. Merhi Z., Garg B., Moseley-LaRue R. et al. Ozone therapy: a potential therapeutic adjunct for improving female reproductive health. Medical Gas Research. 2019;9(2):101–05. doi: 10.4103/2045–912.260652

40. Wei A., Feng H., Jia X. M. et al. Ozone therapy ameliorates inflammation and endometrial injury in rats with pelvic inflammatory disease. Biomedicine & Pharmacotherapy. 2018;107:1418–425. doi: 10.1016/j.biopha.2018.07.137

41. Wang D., Jiang Y., Feng J. et al. Evidence for the Use of Complementary and Alternative Medicine for Pelvic Inflammatory Disease: A Literature Review. Evid Based Complement Alternat Med. 2022:1364297. doi: 10.1155/2022/1364297

42. Gaidukov S. N., Vorobtsova I. N., Konovalova M. V. Effectiveness of complex ozone therapy in inflammatory diseases of the uterine appendages. Bulletin of the Novgorod State University. 2021;1(122):117–20 doi: 10.34680/2076–052 (in Russ.).

43. Tsallagova L. V., Maisuradze L. V., Magaeva F. Yu. The effectiveness of non-drug methods of treatment of chronic inflammatory diseases of the uterine appendages. Spa medicine. 2015;1:56–0 (in Russ.).

44. Khutieva S. V., Maisuradze L. V., Tsallagova L. V. Experience of using complex restorative treatment of patients with chronic inflammatory diseases of the uterine appendages. Kuban Scientific Medical Bulletin. 2017;24(4):146–49. https://doi.org/10.25207/1608-228-017-4-46-49 (in Russ.).

45. Gusak Yu.K., Rischuk S. V., Tarasov V. N. et al. Infectious diseases of the vagina. The search for the optimal solution in their therapy. Defense or attack? (Literature review). Bulletin of New Medical Technologies. 2019;4:22–0. doi: 10.24411/2075-094-019-6485 (in Russ.).

46. Aylamazyan E. K., Ponomarenko G. N., Kondrina E. F. Infrared laser therapy in the complex treatment of patients with chronic salpingoophoritis. Questions of balneology, physiotherapy and therapeutic physical culture. 2015; 6:20–3 (in Russ.).

47. Liu. J. Y. Therapeutic effect of hyperbaric oxygen adjuvant therapy on 29 cases of premature ovarian failure. Chinese Journal of Naut. Med High Press Medicine. 2020; 27:510–12.

48. Lou W. G., Ai L. L., Lin Y. T. Clinical efficacy and mechanism of hyperbaric oxygen combined with drugs in the treatment of chronic pelvic inflammation. Chinese Journal of Naut. Med High Press Medicine. 2016; 23:312–14.

49. Li S. G. Effect of hyperbaric oxygen on treatment of chronic pelvic inflammation in 56 cases. Chinese Journal of Naut. Med High Press Medicine. 2015; 22: 503–04.

50. Han. Q. S. Clinical observation of 66 cases of chronic pelvic inflammatory diseases treated by hyperbaric oxygen combined with traditional Chinese and western medicine. Chinese Journal of Naut. Med High Press Medicin. 2016; 23:239–40.v